Re: Farmas USA
LEXINGTON, MA--(Marketwired - February 12, 2016) - Xenetic Biosciences, Inc. (XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics ("Xenetic") announced today that OPKO Health, Inc. (OPK) has acquired an approximate 6.3% interest in Xenetic.
Commenting on the investment in Xenetic, Dr. Phillip Frost, CEO and Chairman of OPKO Health, Inc., stated, "Xenetic has many novel technologies that address unmet needs in various orphan cancer indications, and we believe the science and the clinical strategy have the promise to create significant shareholder value."
Scott Maguire, President and Chief Executive Officer of Xenetic commented, "We are proud to have OPKO Health as one of our largest shareholders joining our other strategic shareholders, Baxalta and Serum Institute of India. Dr. Frost has an outstanding track record in creating shareholder value in our industry."
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. OPKO's diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. OPKO's pharmaceutical business features Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro, IV formulation in Phase 3). OPKO's biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (entering Phase 2a). OPKO also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.
XBIO
